SecSonar.com

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Tarsus Pharmaceuticals, Inc. (TARS) is a Biotechnology company based in US with a market capitalization of $2.6B. Revenue grew 146.7% year-over-year and free cash flow was negative at -$22.3M. This page tracks TARS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 323 employees · IPO Oct 16, 2020

Valuation

Valuation & price

$62.48 · as of May 17, 2026 · -24.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.45

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$82.51$60.67$38.82Jul 25Dec 25Jul 26Jul 7, 25$39.93Jul 9, 25$41.29Jul 11, 25$39.18Jul 15, 25$40.58Jul 17, 25$41.40Jul 21, 25$42.18Jul 23, 25$42.22Jul 25, 25$41.50Jul 29, 25$40.14Jul 31, 25$38.82Aug 4, 25$41.91Aug 6, 25$41.64Aug 11, 25$50.07Aug 13, 25$52.72Aug 15, 25$54.21Aug 19, 25$53.70Aug 21, 25$56.56Aug 25, 25$56.61Aug 27, 25$57.82Aug 29, 25$58.58Sep 3, 25$57.72Sep 5, 25$57.63Sep 9, 25$56.49Sep 11, 25$51.87Sep 16, 25$50.60Sep 18, 25$54.03Sep 22, 25$55.63Sep 24, 25$55.26Sep 26, 25$56.29Sep 30, 25$59.43Oct 2, 25$58.77Oct 6, 25$67.72Oct 8, 25$69.75Oct 10, 25$70.14Oct 14, 25$69.83Oct 16, 25$74.97Oct 21, 25$70.82Oct 23, 25$68.32Oct 27, 25$68.17Oct 29, 25$67.52Oct 31, 25$68.81Nov 4, 25$71.50Nov 6, 25$68.09Nov 10, 25$72.79Nov 12, 25$74.81Nov 14, 25$72.92Nov 18, 25$76.97Nov 20, 25$76.98Nov 25, 25$78.88Nov 28, 25$79.96Dec 2, 25$79.44Dec 4, 25$81.83Dec 8, 25$82.23Dec 10, 25$81.32Dec 12, 25$81.35Dec 16, 25$78.28Dec 18, 25$77.48Dec 22, 25$81.98Dec 24, 25$82.51Dec 29, 25$81.97Jan 2, 26$80.77Jan 6, 26$79.88Jan 8, 26$78.21Jan 12, 26$75.53Jan 14, 26$75.23Jan 16, 26$71.14Jan 21, 26$71.17Jan 23, 26$68.36Jan 27, 26$68.15Jan 29, 26$65.71Feb 2, 26$65.93Feb 4, 26$63.51Feb 9, 26$65.50Feb 11, 26$65.39Feb 13, 26$60.78Feb 18, 26$63.27Feb 20, 26$66.61Feb 24, 26$75.01Feb 26, 26$75.87Mar 2, 26$77.43Mar 4, 26$76.20Mar 6, 26$73.26Mar 10, 26$73.02Mar 12, 26$68.17Mar 17, 26$69.79Mar 19, 26$66.75Mar 23, 26$64.13Mar 25, 26$66.96Mar 27, 26$66.25Mar 31, 26$70.15Apr 2, 26$70.12Apr 7, 26$68.76Apr 9, 26$72.43Apr 13, 26$72.65Apr 15, 26$71.80Apr 17, 26$67.24Apr 22, 26$63.48Apr 24, 26$61.45Apr 28, 26$62.09Apr 30, 26$63.61May 4, 26$64.57May 6, 26$64.76May 8, 26$61.21May 12, 26$59.83May 14, 26$65.18May 18, 26$62.82May 20, 26$64.79May 22, 26$62.26May 28, 26$59.54Jun 1, 26$58.93Jun 3, 26$58.76Jun 5, 26$59.28Jun 9, 26$61.55Jun 11, 26$62.61Jun 15, 26$61.85Jun 17, 26$62.55Jun 22, 26$63.56Jun 24, 26$67.11Jun 26, 26$62.92Jul 2, 26$65.44
$38.8252-week range$82.51
Loading valuation history…

Fundamentals

Key fundamentals

$2.6B

Market cap

146.7%

Revenue growth (YoY)

93.2%

Gross margin

-$22.3M

Free cash flow (USD)

-$323.6M

Net debt

Net cash position

11.1%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$57.0MFY 2022$25.8MFY 2023$17.4MFY 2024$183.0MFY 2025$451.4M
$0$451.4M

Free cash flow by year

2018 → 2025

FY 2018$-1.2MFY 2019$-3.8MFY 2020$-21.6MFY 2021$3.2MFY 2022$-49.5MFY 2023$-123.0MFY 2024$-84.6MFY 2025$-22.3M
-$1.2M-$22.3M

Gross margin by year

2021 → 2025

FY 202196.4%FY 202296.3%FY 202390.9%FY 202493.0%FY 202593.2%
96.4%93.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 29, 2026Filing
  • Insider sellInsider Sell $615K · 10b5-1 PlanAzamian Bobak R. · Director, President/CEO and Board Chair · $615.5KJun 22, 2026Filing
  • Insider sellInsider Sell $776K · 10b5-1 PlanLINK WILLIAM J PHD · Director · $776.5KJun 17, 2026Filing
  • Insider sellInsider Sell $183K · 10b5-1 PlanGoodrich Katherine · Director · $183.4KJun 17, 2026Filing
  • Insider sellInsider Sell $877KFarrow Jeffrey S · See Remarks · $877.4KJun 17, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is Tarsus Pharmaceuticals, Inc.'s market cap?

Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.6B.

What is TARS's P/E ratio?

A meaningful P/E ratio is not available for TARS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TARS's price-to-book (P/B) ratio?

TARS trades at 7.45 times book value per share.

Are insiders buying TARS stock?

SEC Form 4 filings show no open-market insider buys at Tarsus Pharmaceuticals, Inc. in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

RCUS

Arcus Biosciences, Inc.

$2.5B

IDYA

IDEAYA Biosciences, Inc.

$2.6B

ADPT

Adaptive Biotechnologies Corporation

$2.5B

ALMS

Alumis Inc. Common Stock

$2.7B

TNGX

Tango Therapeutics, Inc.

$2.4B

ARQT

Arcutis Biotherapeutics, Inc.

$2.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.